Admare BioInnovations



2405 Wesbrook Mall, Fourth Floor

Vancouver, BC V6T 1Z3 Canada

Phone: (604)827-1147

Fax: (604)827-1299

Member Sector: Academic & Research Institutions

adMare BioInnovations is a pan-Canadian enterprise with global reach, changing the landscape of the Canadian life sciences ecosystem. Working from sea to sea, and reaching globally, adMare is focused on building a national life sciences industry commensurate with our research leadership. We do this by sourcing the most therapeutically and commercially promising research from leading academic and biotech partners to create new companies of scale, providing specialized expertise and infrastructure to help existing companies scale up, and driving the growth of those companies into Canadian anchors by training the next generation of highly-qualified personnel.

adMare (formerly known as CDRD) was founded in 2007, enabled by the support of the federal government (most notably through the Centres of Excellence for Commercialization and Research (CECR) program), the BC provincial government, and the private sector. Now with a proven track record of results, adMare is firmly positioned as a central leader in Canada’s innovation ecosystem.
The organization has spun-off 8 companies, cultivated strategic partnerships with over 50 affiliated universities and research institutes, 26 Canadian health sciences SMEs/entrepreneurs, 6 top global pharmaceutical companies, 8 of the world’s leading translational research centres, and 3 patient-focused foundations. Through this extensive network, and relationships with the most influential Key Opinion Leaders, decision makers, and supporters shaping Canadian and global innovation, CDRD brings together the complementary expertise and resources required to proactively find, collaboratively develop, and commercialize disruptive, game-changing technologies certainly for patients, but also for the commercial success of strong new Canadian health sciences anchor companies that will result.

More info at Follow us on Twitter: